Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D sufficiency and bone/muscle effects during weekly GH replacement in adult GH deficiency
jRCTs051250164Recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in adult onset growth hormone deficiency (AGHD) and Vitamin D deficiency (VDD) comparing Somatropin + alfacalcidol, Somatropin alone and Alfacalcidol alone (3 arms). Primary endpoint: Change in lumbar spine bone mineral density. Started Apr 2026; status: recruiting.
02
Drugs
somatropinalfacalcidol
03
Conditions
adult onset growth hormone deficiency (AGHD)Vitamin D deficiency (VDD)
Beyond the preview
Go deeper on jRCTs051250164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051250164.